Skip to main content
  • T Cell Response Not Critical for Immune Memory to SARS-CoV-2 or Recovery from COVID-19

    New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections. T cell depletion does not induce severe disease, and T cells do not account for the natural resistance of rhesus macaques to severe COVID-19. Furthermore, strongly T cell-depleted macaques still develop potent memory responses to a second infection. 

  • Regdanvimab demonstrates strong neutralising activity against Delta variant of COVID-19

    Celltrion Group today announced new results from an in vivo efficacy study showing that regdanvimab, CT-P59 has a strong neutralising effect against the rapidly spreading Delta variant, B.1.617.2, first identified in India.

    According to the World Health Organization, WHO, the Delta variant has been reported in 96 countries becoming the most common variant.1

  • Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19

    Cipla Limited, Dr. Reddy’s Laboratories Ltd, Emcure Pharmaceuticals Limited, Sun Pharmaceutical Industries Limited and Torrent Pharmaceuticals Limited announced that the five companies will collaborate for the clinical trial of the investigational oral anti-viral drug Molnupiravir for the treatment of mild COVID-19 in an outpatient setting in India.

  • Pharmacy Recruitment under Health and Family Welfare Department, MCC

    Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighbouring parts of Karnataka and Tamilnadu states.

  • Strides partnered with Ennaid for AI based COVID-19 medicine

    Strides Pharma Science Limited announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.

Subscribe to COVID‐19

Search this website